Hawthorne, NY-based Acorda Therapeutics yesterday released Phase III clinical trial data of fampridine-SR, a novel treatment that improves walking ability in Multiple Sclerosis patients.
Acorda filed a New Drug Application for fampridine on January 30, and FDA approval is expected in about 10 months. If green-lighted, fampridine will be the first drug approved with the indication [...]
PharmExec Blog
Follow Us
RSS
Bookstore
Acorda Seeking NDA for MS Drug